Teacher Retirement System of Texas Sells 3,770 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Teacher Retirement System of Texas lessened its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 8.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 39,795 shares of the biopharmaceutical company’s stock after selling 3,770 shares during the period. Teacher Retirement System of Texas’ holdings in TG Therapeutics were worth $1,569,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Clearbridge Investments LLC acquired a new position in shares of TG Therapeutics in the fourth quarter valued at approximately $55,237,000. Raymond James Financial Inc. acquired a new position in shares of TG Therapeutics in the fourth quarter valued at approximately $14,508,000. Norges Bank acquired a new position in shares of TG Therapeutics in the fourth quarter valued at approximately $12,085,000. Penn Capital Management Company LLC acquired a new position in shares of TG Therapeutics in the fourth quarter valued at approximately $10,577,000. Finally, First Trust Advisors LP boosted its holdings in shares of TG Therapeutics by 871.7% in the fourth quarter. First Trust Advisors LP now owns 275,496 shares of the biopharmaceutical company’s stock valued at $8,292,000 after buying an additional 247,145 shares during the period. Institutional investors own 58.58% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group upgraded shares of TG Therapeutics to a “hold” rating and set a $37.00 target price for the company in a report on Thursday. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.80.

TG Therapeutics Stock Performance

Shares of TGTX opened at $37.08 on Friday. TG Therapeutics, Inc. has a 12 month low of $16.65 and a 12 month high of $46.48. The firm has a fifty day simple moving average of $36.05 and a 200 day simple moving average of $35.28. The stock has a market capitalization of $5.89 billion, a price-to-earnings ratio of 154.50 and a beta of 1.91. The company has a current ratio of 4.02, a quick ratio of 3.04 and a debt-to-equity ratio of 1.03.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a return on equity of 18.88% and a net margin of 10.13%. The business had revenue of $120.86 million for the quarter, compared to analyst estimates of $117.07 million. During the same quarter in the previous year, the company posted ($0.07) EPS. The business’s revenue for the quarter was up 90.4% compared to the same quarter last year. Research analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Insider Buying and Selling

In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of the stock in a transaction on Friday, June 13th. The shares were sold at an average price of $36.94, for a total value of $369,400.00. Following the completion of the sale, the director owned 228,816 shares in the company, valued at $8,452,463.04. This trade represents a 4.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 10.64% of the stock is currently owned by corporate insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.